Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of tirzepatide. Weekly tirzepatide injections significantly ...

Essence may receive compensation for some links to products and services on this website. Offers may be subject to change ...

From left, Bill Walters, Mark Shields, Danielle Nolan, Kate Nolan, Alice Susemichel, John Elliott holding the check for ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

Eli Lilly, makers of Mounjaro and Zepbound ... of Boards of Pharmacy has sent up a Safe Site Search Tool which allows users to verify if a website selling medications has been vetted. You can also ...

Q3 2024 Earnings Call Transcript November 6, 2024Amphastar Pharmaceuticals, Inc. misses on earnings expectations.

Semaglutide has been on the FDA's shortage list since 2022, which has enabled compounding pharmacies and manufactures to make their own, unapproved versions of the drug. Novo Nordisk in October ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...